Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.42 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15973685 | 1.00 | BCHE (0.47) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL18573703 | 1.00 | BCHE (0.47) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL20107401 | 1.00 | BCHE (0.47) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL12310553 | 0.95 | BCHE (0.45) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL17368115 | 0.91 | BCHE (0.44) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL19226960 | 0.87 | IDO1 (0.43) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL19227052 | 0.87 | IDO1 (0.43) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL20741979 | 0.87 | BCHE (0.41) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL19226963 | 0.87 | IDO1 (0.43) | BCHEACHEPDPK1MTORPSEN1 | |
| SCHEMBL18264985 | 0.83 | PSEN1 (0.43) | BCHEACHEPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119125348-A | Detection method for specific impurities in LH-1801 sugar fragment | 扬州市普林斯医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3315502-B1 | C,O-SPIRO ARYL GLYCOSIDE COMPOUNDS, PREPARATION THEREFOR AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2024-07-31 | — | — | EP | disclosed |
| WO-2022151615-A1 | SYNTHESIS METHOD FOR TIANAGLIFLOZIN INTERMEDIATE | 广州市力鑫药业有限公司 | 2022-07-21 | — | — | WO | disclosed |
| WO-2022062401-A1 | PREPARATION METHOD FOR TIANAGLIFLOZIN | 广州市力鑫药业有限公司 | 2022-03-31 | — | — | WO | disclosed |
| US-10550143-B2 | C,O-spiro aryl glycoside compounds, preparation therefor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-02-04 | — | — | US | disclosed |
| US-10550143-B2 | C,O-spiro aryl glycoside compounds, preparation therefor and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-02-04 | — | — | US | disclosed |
| EP-3315502-A1 | C,O-SPIRO ARYL GLYCOSIDE COMPOUNDS, PREPARATION THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550143-B2 | C,O-spiro aryl glycoside compounds, preparation therefor and use thereof | SLC5A2, SLC5A1, GLP1R | BCHE 3626/4885ACHE 4202/4885PDPK1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.